Pacific Biosciences Of California reported $304.43M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Accelerate Diagnostics AXDX:US USD 38.99M 34.41M
Agilent A:US USD 1.05B 18M
Bruker BRKR:US USD 626.2M 96.8M
Danaher DHR:US USD 5.15B 1.17B
Fluidigm FLDM:US USD 60.2M 14.16M
General Electric GE:US USD 12.6B 594M
Illumina ILMN:US USD 1000M 289M
Myriad Genetics MYGN:US USD 110.7M 86.6M
Nanostring Technologies NSTG:US USD 117.07M 8.96M
Pacific Biosciences Of California PACB:US USD 304.43M 6.01M
Quidel QDEL:US USD 212.2M 166.8M
Roche Holding ROG:VX 4.32B 2.54B
Thermo Fisher Scientific TMO:US USD 2.92B 1.03B
Waters WAT:US USD 444.51M 25.62M